Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
-
We next considered the effect of alkyl chain
2024-11-04
We next considered the effect of alkyl chain length on the inhibitory activity. As can be seen from , it is obvious that there is no proportional relationship between the methylene chain length and activity. The activity decreased when the chain length increased from 1 to 3 and increased with elonga
-
Introduction Adenosine monophosphate cAMP is a general
2024-11-04
Introduction Adenosine 3′,5′-monophosphate (cAMP) is a general-purpose signaling molecule present in most branches of life. Intracellular cAMP levels control diverse cellular functions. In bacteria, cAMP regulates metabolism by activation of the catabolite activator protein (CAP), also known as cAM
-
Regarding A Rs and A ARs basal
2024-11-04
Regarding A1Rs and A2ARs, basal conditions generate a low tone of endogenous adenosine and cause A1R activation, in contrast to situations of increased adenosine where A2AR activation becomes dominant. When adenosine concentrations rise, e.g. during hypoxia, also time appears likely important in reg
-
ADA catalyzes the deamination of adenosine and
2024-11-04
ADA catalyzes the deamination of adenosine and deoxyadenosine into their respective inosine nucleoside (Cristalli et al., 2001). This conversion is an initial step in a series of reactions responsible for lymphocyte proliferation and differentiation. Moreover, ADA is considered an indicator of cellu
-
br Occurrence of Inosine in RNA
2024-11-04
Occurrence of Inosine in RNA Inosine is widespread among various types of RNAs including transfer RNA (tRNA), ribosomal RNA (rRNA), messenger RNA (mRNA), long noncoding RNA (lncRNA), and microRNA (miRNA). Within these RNAs, inosine can appear in different locations as well. Table 1 lists examples
-
The use of a single well identified molecule to
2024-11-04
The use of a single well-identified molecule to induce AChR clusters formation can simplify complicated cell manipulation procedures and may provide a more efficient means of developing biological substitutes for functional muscle tissue restoration in vivo. Pharmacological approaches dealing with b
-
The inhibition of the exacerbated inflammatory response
2024-11-01
The inhibition of the exacerbated inflammatory response that follows injury may be an alternative approach to induce a more efficient repair [17,83]. In line with that, 5-LO is one of the most consolidated targets for dampening inflammation, mainly through the therapeutic effects of 5-LO inhibitors
-
Notably our preliminary results confirmed
2024-11-01
Notably, our preliminary results confirmed that fluoxetine (SSRIs, 5–10 mg/kg) and duloxetine (SNRIs, 5–10 mg/kg) could not enhance memory function in the novel object recognition or step-down passive avoidance tasks (data not shown). In the present study, we also found that vilazodone showed had no
-
Furthermore new strategies to achieve a
2024-11-01
Furthermore, new strategies to achieve a total androgen deprivation namely by blocking either androgen biosynthesis as well as AR are being considered and should be a relevant topic in the near future. A successful example of this approach is galeterone (159), which not only inhibits the CYP17 enzym
-
br Introduction Human esophageal carcinoma is one
2024-11-01
Introduction Human esophageal carcinoma is one of the most frequently diagnosed cancers, ranked as the eighth leading causes of cancer-related mortality worldwide. Esophagus squamous cell carcinoma (ESCC) is the most common histological type of esophageal carcinomas, especially with a higher inci
-
The identification of novel kinase inhibitor
2024-11-01
The identification of novel kinase inhibitor scaffolds is highly desirable in order to develop selective kinase inhibitors. Small-molecule inhibitors of Interleukin-2-inducible T-cell kinase (Itk) that are based on the 3-aminopyridin-2-one fragment 1 have been reported. Despite derivatisation of 1 y
-
The synthetic route for the
2024-11-01
The synthetic route for the aminobenzoxazole scaffold with a solvent accessible moiety is described in . Nitration of methoxyphenol and subsequent hydrogenation of the resulting nitro brain metabolism afforded compound . Aminobenzoxazole was formed by the reaction of compound with BrCN in EtOH. T
-
Ryoichi et al modified potent clinical candidate VX with cya
2024-11-01
Ryoichi et al. modified potent clinical candidate VX-680 (6) with 3-cyano-6-(5-methyl-3-pyrazolamino)pyridine as Aurora kinase inhibitor. Substituted cyano pyridine derivative (7) inhibited proliferation of HCT-116 cells with an IC50 value of 115 nM. It showed tumor inhibition in mice model at a dos
-
Several genes related to metabolism post
2024-11-01
Several genes related to metabolism, post-transcriptional regulation, chromatin structure, and signaling pathways are required for the sexual development and virulence of G. zeae (Baldwin et al., 2010, Bluhm et al., 2007, Ding et al., 2009, Han et al., 2007, Hou et al., 2002, Jenczmionka et al., 200
-
A high throughput screening campaign
2024-11-01
A high-throughput screening campaign led to the discovery of the first series of both potent and selective ATR kinase inhibitors by Vertex Pharmaceuticals (Charrier et al., 2011). One of these compounds, VE-821, was shown to be a potent ATP-competitive inhibitor of ATR with minimal cross-reactivity
15446 records 25/1030 page Previous Next First page 上5页 2122232425 下5页 Last page